The most lethal cancer in both the United States and the rest of the globe is lung cancer. Patients have few options because many of the currently available medicines are useless. Bacterial therapy has been a promising new approach to treating cancer; however, even though this treatment method has swiftly advanced from laboratory studies to clinical trials in the last five years, the most efficient treatment for some types of malignancies may be in combination with other medications. In order to characterise bacterial therapeutics in lung cancer models, Columbia Engineering researchers have created a preclinical evaluation pipeline. Their most recent research, which was released by Scientific Reports, mixes bacterial therapeutics with other therapy modalities to increase treatment efficacy while minimising side effects. With the use of this novel method, bacterial medicines could be quickly characterised and successfully incorporated into existing lung cancer-targeted therapies. The scientists employed RNA sequencing to identify the cellular and molecular mechanisms by which cancer cells reacted to bacteria. They developed a theory regarding the cancer cells' molecular pathways that contributed to their resistance to the bacterial therapy. The researchers used current cancer treatments to inhibit these pathways in order to verify their theory, and they then demonstrated that adding bacterial toxins to the medications increased their ability to kill lung cancer cells. In animal models of lung cancer, they verified the efficacy of combining bacteria therapy with an AKT inhibitor, as an example. The utilisation of toxins produced by bacteria is described in this new study as a promising therapeutic development pathway that has not before been investigated in lung cancer. Preclinical information reported in the study offers a compelling case for further investigation in this field, potentially resulting in novel therapeutic choices for people suffering from this fatal condition.